Results 241 to 250 of about 307,381 (359)

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source

Stem cell therapy in systemic sclerosis. [PDF]

Clin Rheumatol
Sakkas LI, Simopoulou T, Alexiou I, Liaskos C, Chikanza IC.   +4 more
europepmc   +1 more source

POS1128 Age of onset effect on the clinical manifestations of patients with Juvenile Systemic Sclerosis

Ivan Foeldvari, J. Klotsche, K. Torok, O. Kasapcopur, A. Adrovic, B. Feldman, Flávio Sztajnbok, Maria Teresa Terreri, Ana Paula Sakamoto, R. Khubchandani, Jordi Antón, Gülcan Özomay Baykal, Stephanie Johnson, D. Schonenberg, V. Stanevicha, Е.I. Alexeeva, M. Katsikas, Sujata Sawhney, V. Smith, S. Abu Al Saoud, Eslam Al‐Abadi, S. Appenzeller, T. Avcin, Natasha Cabrera, S Hájek, Mikhail M. Kostik, T. Lehman, S. Li, Hana Malcová, E. Marrani, S. Opsahl Hetlevik, C. Pain, A. Patwardhan, Walter Alberto Sifuentes Giraldo, N. Vasquez-Canizares, Patrícia Costa‐Reis, M. Janarthanan, M. Moll, Dana Němcová, C. Battagliotti, L. Berntson, B. Bica, J. Brunner, D. Eleftheriou, L. Harel, G. Horneff, Daniela Kaiser, T. Kallinich, Dragana Lazarević, J.M. López Benítez, K. Minden, Søren Nielsen, Farzana Nuruzzaman, Mihaela Spârchez, Y. Uziel, N. Helmus   +55 more
openalex   +1 more source

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial

Arthritis &Rheumatology, EarlyView.
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih, Shiow‐Ing Wang, Qing‐Wen Wang, James Cheng Chung Wei   +3 more
wiley   +1 more source

GLUT and FAPα as molecular markers for interstitial lung disease in systemic sclerosis. [PDF]

Respir Res
Broens B, van der Laken CJ, Radonic T, Nossent EJ, Manz XD, Mulder DJ, Al-Adwi Y, Gan CT, Timens W, Voskuyl AE, Duitman JW.   +10 more
europepmc   +1 more source

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

Arthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp   +14 more
wiley   +1 more source

Development of a conceptual model of early systemic sclerosis (scleroderma). [PDF]

Orphanet J Rare Dis
Lenderking WR, Ladd MK, Barnes N, Braverman J, Gasior M, Hofmann J, Lawo JP, Khanna D.   +7 more
europepmc   +1 more source

Telomere Length of Peripheral Blood Leukocytes Predicts Disease Severity and Worse Survival in Systemic Sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective Peripheral blood leukocyte telomere length (PBL‐TL) shortening is associated with systemic sclerosis related interstitial lung disease (SSc‐ILD). However, its association with other organ involvement, disease severity, and survival remains unclear.
Monica M. Yang, Shuo Liu, Michael Wax II, Seoyeon Lee, Sarah French, Paul J. Wolters, Francesco Boin   +6 more
wiley   +1 more source

Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis. [PDF]

Rheumatology (Oxford)
Velauthapillai A, Bootsma MFR, Bruni C, Bergmann C, Matucci-Cerinic M, Launay D, Riemekasten G, Garzanova L, Airò P, Rezus E, da Silva JAP, Del Galdo F, Hunzelmann N, Chung LS, Krasowska D, Distler O, van den Ende CHM, Vonk MC, EUSTAR Collaborators .   +18 more
europepmc   +1 more source

MiR-3606-3p inhibits systemic sclerosis through targeting TGF-β type II receptor

, 2018
Xiangguang Shi, Qingmei Liu, Na Li, Wenzhen Tu, Ruoyu Luo, Xueqian Mei, Yanyun Ma, Weihong Xu, Haiyan Chu, Shuai Jiang, Zhimin Du, Zhao Han, Liang Zhao, Jin Li, Wenyu Wu, Jiucun Wang   +15 more
openalex   +1 more source